RESTON, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SJOGREN'S FOUNDATION INC, founded in 1983, is a community nonprofit in the Diseases & Disorders sector that reported $5.3M in total revenue in fiscal year 2024. Revenue surged 51% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.1M, a strong 20% operating margin.
THE FOUNDATION'S MISSION IS TO PROVIDE EDUCATION AND RESOURCES TO SJOGREN'S PATIENTS AND THEIR LOVED ONES, PROVIDE CREDIBLE RESOURCES/EDUCATION TO HEALTHCARE PROFESSIONALS, SERVE AS THE VOICE OF ALL PATIENTS THROUGH ADVOCACY AND FUND INNOVATIVE RESEARCH.
THE SJOGREN'S FOUNDATION AWARDED FOUR RESEARCH GRANTS UNDER THE ANNUAL SJOGREN'S FOUNDATION GRANT PROGRAM TO UNIVERSITY AFFILIATED RESEARCHERS IN JUNE 2025. THREE PILOT GRANTS WERE AWARDED AND ONE...
THE SJOGREN'S FOUNDATION AWARDED FOUR RESEARCH GRANTS UNDER THE ANNUAL SJOGREN'S FOUNDATION GRANT PROGRAM TO UNIVERSITY AFFILIATED RESEARCHERS IN JUNE 2025. THREE PILOT GRANTS WERE AWARDED AND ONE HIGH IMPACT GRANT AWARDED. THE SJOGREN'S FOUNDATION ALSO AWARDED A DYNAMIC GRANT TO THE UNIVERSITY OF UTAH FOR DEVELOPMENT OF INTERNATIONAL CLASSIFICATION CRITERIA FOR CHILDREN WITH SJOGREN'S DISEASE. THE FOUNDATION PAID THE THIRD PAYMENT TO SUPPORT THE FOUNDATION FOR THE NIH AMP AIM RESEARCH PROJECT ON SJOGREN'S AND OTHER AUTOIMMUNE DISEASES, AND THE FIRST PAYMENT OF THE NEW FOUNDATION FOR THE NIH SJOGREN'S BIOMARKERS CONSORTIUM PROJECT TO DISCOVER NEW BIOMARKERS FOR SJOGREN'S TO AID IN IMPROVED DIAGNOSIS AND TREATMENT.THE SJOGREN'S FOUNDATION ALSO WORKED CLOSELY WITH MULTIPLE PHARMA COMPANIES TO PREPARE FOR, AND BRING, PHASE 2 AND PHASE 3 CLINICAL TRIALS FORWARD. THE FOUNDATION SUPPORTED THESE PROGRAMS BY CONFERRING WITH PHARMA ON PROTOCOLS AND PATIENT NEEDS, CERTIFYING CLINICAL TRIAL INVESTIGATORS ON PROPER USE OF ESSDAI OUTCOME MEASURES, AND ENGAGING PATIENTS TO ENCOURAGE TRIAL ENROLLMENT, IN ORDER TO HELP BRING THERAPIES TO MARKET.
NEWSLETTER - THE FOUNDATION PRODUCES TWO NEWSLETTERS. "CONQUERING SJOGREN'S" IS A PATIENT FOCUSED NEWSLETTER WITH INFORMATION ABOUT SJOGREN'S AND ITS MANY MANIFESTATIONS. CS IS PRODUCED BI-MONTHLY...
NEWSLETTER - THE FOUNDATION PRODUCES TWO NEWSLETTERS. "CONQUERING SJOGREN'S" IS A PATIENT FOCUSED NEWSLETTER WITH INFORMATION ABOUT SJOGREN'S AND ITS MANY MANIFESTATIONS. CS IS PRODUCED BI-MONTHLY. THE "SJOGREN'S QUARTERLY" IS A PROFESSIONAL PUBLICATION PRODUCED 4 TIMES A YEAR AND OFFERED FREE TO ALL HEALTHCARE PROFESSIONALS TO INCREASE AWARENESS AND EDUCATION AROUND SJOGREN'S.
THE SJOGREN'S FOUNDATION INCREASED PATIENT SUPPORT AND EDUCATION PROGRAMS IN 2025 AS WELL AS HEALTHCARE PROVIDER EDUCATION AND AWARENESS ABOUT SJOGREN'S AND THE SYSTEMIC, MULTI-FACETED NATURE OF THE...
THE SJOGREN'S FOUNDATION INCREASED PATIENT SUPPORT AND EDUCATION PROGRAMS IN 2025 AS WELL AS HEALTHCARE PROVIDER EDUCATION AND AWARENESS ABOUT SJOGREN'S AND THE SYSTEMIC, MULTI-FACETED NATURE OF THE DISEASE. OF NOTE WAS THE EXPANSION OF PROVIDER OUTREACH THROUGH STATE OF SJOGREN'S AND THE FOUNDATION'S CME PROGRAM AS WELL AS PARTNERING WITH EXTERNAL CME PROGRAMS FOR SPECIALTIES AND PRIMARY CARE PROVIDERS. THE FOUNDATION ALSO INCREASED OUR ADVOCACY EFFORTS TO HIGHLIGHT THE IMPORTANCE OF CONTINUED AUTOIMMUNE DISEASE RESEARCH FUNDING, ESPECIALLY FOR SJOGREN'S AND TO HIGHLIGHT THE IMPORTANCE OF SUPPORTING THE OFFICE OF AUTOIMMUNE DISEASE RESEARCH. WE SUCCEEDED IN GETTING A NEW HOUSE RESOLUTION #245 TO AFFIRM APRIL AS SJOGREN'S AWARENESS MONTH WHICH INCLUDED MESSAGING ABOUT THE NEED FOR MORE RESEARCH AND WE HELD OUR FIRST CONGRESSIONAL BRIEFING ON SJOGREN'S. THE FOUNDATION ALSO CONTINUED OUR DIALOG WITH CENTERS FOR MEDICARE AND MEDICAID FOR DENTAL COVERAGE. WE CONTINUED TO ADVANCE OUR RELATIONSHIPS WITH CLINICIANS, RESEARCHERS, GOVERNMENT SCIENTISTS, AND CORPORATE SCIENTISTS WHO ARE INTERESTED IN SJOGREN'S. IN JUNE 2025, THE FOUNDATION WORK TO CHANGE THE DISEASE NAME FROM SJOGREN'S SYNDROME TO SJOGREN'S DISEASE WAS INTERNATIONALLY CONFIRMED BY THE PUBLICATION OF THE INITIATIVE IN A PEER-REVIEWED PUBLICATION NATURE REVIEWS RHEUMATOLOGY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $5,277,586 | $3,497,666 | +0.5% |
| Expenses | $4,223,979 | $3,174,412 | +0.3% |
| Net Income | $1,053,607 | $323,254 | +2.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| SUSAN BARAJAS | CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| DONALD E THOMAS MD | PAST CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| VIDYA SANKAR DMD MHS | TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| KATIE FORTE | SECRETARY | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ALAN BAER MD | DIRECTOR, CHAIRMAN OF MSAC | 2.00 |
Director
|
$0 | $0 | $0 |
| ALLISSA LATHAM | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| BRENT P GOODMAN MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DANIEL WALLACE MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID SCHRADER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| NISHANT GUPTA MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| ROBYN LAUKIEN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| RUBENSTEIN LISA | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SARA MCCOY MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SCOTT LIEBERMAN MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| TAMMY DOTSON | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| TOM IATESTA | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| VATINEE BUNYA MD MSCE | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JANET CHURCH | PRESIDENT AND CEO | 40.00 |
Officer
|
$368,360 | $0 | $368,360 |
| KATHERINE MORLAND HAMMITT | VP OF MEDICAL AND SCIENTIFIC AFFAIRS | 40.00 |
Key Emp
|
$189,280 | $0 | $189,280 |
| BEN BASLOE | VP OF PHILANTHROPY AND OPERATIONS | 40.00 |
Highest
|
$135,085 | $0 | $135,085 |
| LANE DESTRO | SR. DIRECTOR, CORPORATE PARTNERSHIPS & STRATEGIC I | 40.00 |
Highest
|
$125,368 | $0 | $125,368 |
| MICHELE CHAMPIGNY | VP OF PATIENT SERVICES AND EDUCATION | 40.00 |
Highest
|
$115,761 | $0 | $115,761 |
| MATTHEW MAKARA | SENIOR DIRECTOR OF RESEARCH & SCIENTIFIC AFFAIRS | 40.00 |
Highest
|
$114,253 | $0 | $114,253 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $5,277,586 | $4,223,979 | $5,240,223 | $1,053,607 |
| 2024 | $3,497,666 | $3,174,412 | $4,167,805 | $323,254 |
| 2023 | $3,324,713 | $2,841,846 | $3,694,277 | $482,867 |
| 2022 | $2,943,480 | $2,322,444 | $2,799,424 | $621,036 |
| 2021 | $2,961,602 | $2,930,916 | $2,612,292 | $30,686 |
| 2020 | $2,468,773 | $2,427,639 | $2,458,865 | $41,134 |
| 2019 | $3,416,389 | $2,342,283 | $2,009,972 | $1,074,106 |
Compare SJOGREN'S FOUNDATION INC with other nonprofits in Virginia and across the country.